EGFR and carcinoma: For example, prospective studies on the expression of EGFR and EpCAM might shed light on the power of EpCAM expression to predict treatment response in carcinoma entities that implement a therapy with the anti-EGFR monoclonal antibody cetuximab or small molecule inhibitors of EGFR.